No prescription formulations of copper peptide GHK-Cu have received FDA approval for any medical indication, and its use is off-label or investigational in clinical contexts
Citation: Vukojevi, J., Kolenc, D., Brcic, I., & Seiwerth, S
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Fatigue during the loading phase this comes from TB-500 and your body's systemic repair kicking in
Possible Joint Support Some preliminary research suggests cartilage-protective properties